uniQure Announces 2019 Financial Results and Highlights Recent Company Progress
02 mars 2020 16h05 HE
|
uniQure Inc.
~ Patient Dosing Nearly Completed in Phase III HOPE-B Trial of Etranacogene Dezaparvovecin Hemophilia B ~ ~ First Patient Procedure in Phase I/II Clinical Trial of AMT-130 in Huntington’s Disease...
uniQure to Participate in Multiple Upcoming Industry Conferences in December
02 déc. 2019 07h00 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 02, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure to Participate in Multiple Upcoming Industry Conferences in November
01 nov. 2019 07h00 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 01, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Third Quarter 2019 Results and Highlights Recent Company Progress
28 oct. 2019 07h00 HE
|
uniQure Inc.
~ Announced Completion of Full Patient Enrollment in HOPE-B Pivotal Study of Etranacogene Dezaparvovec ~ ~ Achieved Site Initiation and Began Patient Screening for Phase I/II Clinical Study of...
uniQure to Participate in Multiple Upcoming Industry Conferences in October
27 sept. 2019 07h00 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 27, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Pricing of its Public Offering
05 sept. 2019 20h39 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 05, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Proposed Public Offering
04 sept. 2019 16h02 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 04, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B
03 sept. 2019 07h00 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 03, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure to Participate in Multiple Upcoming Industry Conferences in September
30 août 2019 07h00 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug. 30, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Leadership Promotions and Executive Transition
20 août 2019 07h00 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug. 20, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...